AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited is a listed pharmaceutical company operating in the health‑care sector on the National Stock Exchange of India. As of 2 September 2026, the company’s closing share price was ₹6,940.50, positioned between a 52‑week low of ₹6,835 and a high of ₹9,849.50. The market capitalisation stands at ₹2,060,000,000, with a price‑to‑earnings ratio of 101.23.

Recent Analyst Coverage

  • Zacks Research (3 September 2026) – In a recent analyst blog, Zacks highlighted AstraZeneca as one of the key stocks in its portfolio. The firm noted that the company’s pipeline and emerging therapeutic areas, particularly in oncology, contribute to a positive outlook for earnings growth. The analysis also referenced the broader pharmaceutical industry trends that are expected to support demand for new treatments.

  • Zacks Stock Report (2 September 2026) – A subsequent report reinforced AstraZeneca’s prominence among the firm’s top‑tier stock recommendations. The report emphasized the company’s strong drug development pipeline and the potential impact of new oncology products on long‑term revenue generation.

Market Context

While the broader market saw modest movements—FTSE 100 was up 0.7 % on 3 September and slightly down 0.3 % on 2 September—AstraZeneca’s inclusion in analyst coverage suggests investor confidence in its strategic positioning. The company’s focus on oncology, particularly in the osteosarcoma segment highlighted in external market research, aligns with industry expectations for growth through innovative therapies.

Key Takeaways

  • Strong Pipeline: AstraZeneca’s drug development pipeline, especially in oncology, is a central factor in positive analyst sentiment.
  • Valuation: The high price‑to‑earnings ratio reflects expectations of significant future earnings growth, consistent with the company’s investment in research and development.
  • Market Position: Despite fluctuations in global indices, AstraZeneca remains a focal point for investors looking for exposure to high‑growth pharmaceutical opportunities.

These points provide a concise overview of AstraZeneca Pharma India Limited’s recent financial standing and analyst perspective, derived solely from the supplied data.